Home › Steatotic Liver Disease › Virginia
Steatotic Liver Disease clinical trials in Virginia
14 studies for Steatotic Liver Disease are looking for participants at sites in Virginia.
Cities in Virginia
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Virginia Commonwealth University, Richmond
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- University of Virginia Medical Center, Charlottesville
- Richmond Veterans Administration Medical Center, Richmond
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Eximia Research - Norfolk, Norfolk
- Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
- Virginia Commonwealth University (VCU) Medical Center, Richmond
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Norfolk
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- and 3 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Manassas
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- and 1 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Richmond
- GSK Investigational Site, Richmond
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Manassas
- GSK Investigational Site, Norfolk
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Richmond
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
- Virginia Commonwealth University, Richmond
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jun 4, 2026 · NCT05424003Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- University of Virginia, Charlottesville
- Virginia Common wealth University, Richmond
Recruiting
Ages 18 to 75 · All sexes · Updated May 19, 2026 · NCT04054310Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
- Virginia Commonwealth University, Richmond
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT05720663From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.